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Introduction
Neurological disorders caused by equine herpesvirus-1 (EHV-1) are called equine herpesvirus-1 associated myeloencephalopathy (EHM) and this is considered a contagious emerging syndrome (Lunn et al., 2009; Kydd et al., 2010; Traub-Dargatz et al., 2013) . Currently, early recognition of suspected cases and close monitoring of high-risk horses represent the most reliable measures for preventing EHM outbreaks and limiting the consequences (Lunn et al., 2009; Pusterla et al., 2009) .
Although clinical signs of EHM are often perceived as well described (Kydd et al., 2010) and clinical diagnosis therefore straightforward, its clinical recognition can be troublesome, especially when isolated cases are considered rather than outbreaks. The diffuse and multifocal distribution of the lesions in the central nervous system (Lunn et al., 2009; Pusterla et al., 2009 ) can cause considerable variability in clinical presentation (van der Meulen et al., 2003; Pusterla et al., 2009 ).
Laboratory analyses therefore remain indispensable, but take up precious time. New tools for improved clinical recognition of EHM would therefore be highly valuable.
Geographical region appears to be associated with EHM development (Goehring et al., 2006; Lunn et al., 2009 ) and risk factors could therefore potentially differ between countries. There are only few reports available in literature on EHM in France (Pronost et al., 2010b; Pronost et al., 2012) and none describe risk factors. Moreover, epidemiological studies are often restricted to a single outbreak, thereby limiting their potential at identifying risk factors unrelated to a specific outbreak. More data establishing possible risk factors are required (Lunn et al., 2009 ).
This study aims at improving the current understanding of EHM by: 1) describing EHM in France, 2) improving early clinical recognition of EHM by identifying variables that are specifically related to EHM rather than to other equine acute neurological diseases, and 3) the identification of host and management related factors.
Methods, techniques

Data collection
In France, a passive epidemiological surveillance program is implemented by the "Réseau d'Epidémio-Surveillance en Pathologie Equine" (RESPE; http://www.respe.net) to detect and monitor emerging and infectious neurological equine diseases, one of which is EHM. Veterinarians throughout France are asked to report all horses with acute neurological signs (all are considered potentially infectious), and to fill in a detailed standardized questionnaire for each case. Laboratory analysis was offered free of charge. There is owner informed consent.
Retrieved data from reported cases and definitions
Detailed information on season, and demographic, management, clinical and laboratory data were retrieved from the reporting veterinarians with use of standardized questionnaires. Cauda equina syndrome was defined as presence of a single or a combination of clinical signs related to lumbosacral cord pathology, i.e. an abnormal tonus, reflexes and sensibility of tail, anus and/or perineum, inability to urinate and/or defecate and urinary incontinence. Urinary retention caused by upper motor neuron lesions was also included in this definition, as reflection of diagnostic difficulties under field conditions.
EHM cases
Reported cases with acute neurological signs (regardless of further clinical and specific neurological signs) and with a positive test result for EHV-1 were considered EHM cases. EHV-1 positive testing was based on recent reviews (Lunn et al., 2009; Pusterla et al., 2009 ): 1) for ante mortem testing, a positive polymerase chain reaction (PCR) on nasal swabs, blood and / or cerebrospinal fluid, 2) for post mortem testing, histology with characteristic lesions in the spinal cord (vasculitis), or positive PCR from nervous tissue, or 3) seroconversion for EHV on acute and convalescent serum (4-fold increase)..
Control cases
The control group included reported cases that: 1) presented with acute neurological signs, and therefore were clinically suspect to have infectious neurological diseases amongst which EHM, and 2) were considered not to be infected with EHV-1 following diagnostic laboratory testing. They were considered EHV negative based on: 1) absence of seroconversion for EHV on paired sera or on a single serum taken > 1 week after disease onset, and/or 2) negative PCR (control cases should not have a positive PCR, but a negative PCR test was considered inadequate to rule out EHM) and/or 3) confirmation or high suspicion of another disease leading to neurological signs. To reduce bias as much as possible, the latter criterium was minimally based on clinical signs and mainly based on additional diagnostic testing.
Laboratory testing
Depending on the samples sent by the reporting veterinarian, complement fixation testing on blood and real-time PCR (on blood, cerebrospinal fluid, nasal swab and/or tissue) were performed as previously described (Pronost et al., 2012; Slater, 2014) .
Statistical methods
To compare the EHM cases versus control cases, frequency variables were assessed by odds ratio (OR), categorical variables were assessed by Fisher's exact test and quantitative variables were assessed by a two-sample Wilcoxon rank-sum test. All variables with a P-value < 0.10 in those univariate analyses were entered in a multivariate logistic regression. In addition, to assess collinearity, a backward elimination of variables was performed. Variables that induced a modification of OR of >20% were retained in final analysis. Goodness of fit was assessed using the Hosmer-Lemeshow goodness-of-fit test (StataCorp, 2012) . Furthermore, classification and regression tree (CART) analysis (Saegerman et al., 2011) were performed to compare history and clinical signs or only clinical signs between groups.
Results
Description
Out of the 219 neurological cases reported to the RESPE from 2008 to 2011, 26 cases fulfilled the inclusion criteria for EHM cases, and 29 for control cases. All EHM cases were considered EHV positive based on a positive PCR for EHV-1 on blood, nasal swab, cerebrospinal fluid and/or nervous tissue. The two cases that underwent a full post-mortem examination furthermore showed typical histology following post-mortem. Table 1 (17) during winter months. No significant seasonal difference was observed between groups (P = 0.47). Some cases occurred together in the same herd or were related to each other, but half of them were unrelated to other cases (13/26). Clinical signs and their comparison between groups are described in Table 3 , and details on neurological signs of EHM cases in Table 4 . Apart from the fact that most EHM cases showed ataxia or paresis and a cauda equina syndrome, the remainder of the clinical picture was found to be variable. The mortality rate of the EHM group was 46%.
Control horses (29) were considered to be EHM negative based on absent seroconversion on paired sera (13), low antibody titre on a single serum taken > 1 week after the onset of clinical signs (2), and/or confirmation or high suspicion of another disease (17; Table 5 ).
Statistical analysis
Introduction of a new horse to the herd, EHV vaccination (but not if EHV vaccination occurred less than 6 months ago), and cauda equina syndrome were variables with a significantly higher association to EHM horses than controls. The herd size was significantly larger for EHM than for controls (Table 2 and 3) . On the multivariate analysis only the introduction of a new horse to the herd (OR = 14.64; 95% CI: 1.32-161.93; P = 0.03) and cauda equina syndrome (OR = 28.49; 95% CI: 1.23-427.07; P = 0.015) could be retained. The CART analysis showed that when variables of history and the clinical exam were used, herd size, month of occurrence and introduction of a new horse in the herd were the best predictors for EHM, and this with a sensitivity of 65% and specificity of 52% for the decision tree. When only the clinical exam was taken in consideration, presence of cauda equina syndrome was the best predictor with a sensitivity of 88% and specificity of 41%.
Discussion
This study provides clinical and epidemiological data on French EHM cases over a period of 4 years. The number of French EHM cases is believed underestimated, because of underreporting of this unnotifiable disease and the associated diagnostic challenges. From these results, it can be suggested that EHM occurs in the form of isolated cases at least as often as in the form of an outbreak, highlighting the need for improved tools for clinical recognition. Besides the fact that most EHM cases showed ataxia and/or paresis and a cauda equina syndrome, the clinical picture of EHM in the reported cases was variable. Some cases were reported with cerebral signs of abnormal behaviour; this is not the most typical expression of EHM, nevertheless it has been previously described (van der Meulen et al., 2003) . This highly variable clinical picture, the atypical neurological expressions and the high number of isolated cases are all likely to be a result of the surveillance format used, where all acute neurological cases were considered as potentially infectious, reported and tested, therefore including EHM cases that might otherwise remain unidentified.
Not unexpectedly, cauda equina syndrome was the only clinical variable significantly more present in EHM horses than in controls. The definition of cauda equina syndrome in this study was rather large, including urinary retention due to both lower motor neuron and upper motor neuron lesions. While probably better reflecting the field conditions, this leads to an overestimation of control cases with a cauda equina syndrome and therefore underestimation of its statistical power and specificity as a predictor for EHM. Nonetheless, its odds ratios are still high. Following the results of this study, it is 28 times more likely that a veterinarian is dealing with EHM than another neurological disease when he or she is called to see a horse with acute neurological symptoms and identifies a cauda equina syndrome. Also in the CART analysis, cauda equina syndrome was considered a main predictor for EHM and showed a good sensitivity. This makes it potentially a very useful clinical indicator as a first screening tool for syndromic surveillance for EHM. Of course after clinical suspicion, laboratory analysis remains necessary.
Age and sex were not statistically different between groups in the current study but it should be noted that, similar to studies performed in The Netherlands (Goehring et al., 2006) , and in the USA (Henninger et al., 2007) EHM was not associated with young age. Nonetheless, EHM has been reported in horses of all ages (Greenwood and Simson, 1980; Friday et al., 2000) . Breed was different between groups in the present study, with more saddle horses in the EHM group. Breed has been previously identified to be a risk factor for EHM (Goehring et al., 2006; Barbic et al., 2012) , with Haflingers, Fjord horses, Icelandic horses and archetypical pony breeds less frequently affected by EHM (Goehring et al., 2006) .
Introduction of horses to a herd before development of EHM outbreaks is commonly reported (van Maanen et al., 2001; van der Meulen et al., 2003; Goehring et al., 2006; Henninger et al., 2007) , and was identified as a risk factor for EHM in this study by all different statistical means.
Following our results, it is 14-15 times more likely to be EHM than another neurological disease when this variable is present in the history of an acute neurological case.
EHV vaccination was not uncommon in all groups and the findings of this study cannot support it to be a risk factor for EHM. Although by univariate analysis EHV vaccination was identified as a risk factor, it could not be retained in the multivariate analysis and more importantly failed as a risk factor in the univariate analysis when only those horses were taken into account where EHV vaccination was performed within the last 6 months before EHM developed. EHV vaccination was reported previously to be associated with EHM (Henninger et al., 2007; TraubDargatz et al., 2013) , but EHM also develops in populations where none or few horses are vaccinated (Goehring et al., 2006) and vaccination status could have been potentially confounded with increasing age (Lunn et al., 2009 ). The current study shows that age is unlikely to be a confounding factor since vaccinated EHM cases were younger than those unvaccinated (12.0 ± 4.2 versus 14.6 ± 3.6 years, respectively).
In this study, the variables significantly different between groups have been identified by statistical comparison of EHM cases to a control group. Both groups potentially have infectious neurological diseases due to the presence of acute neurological signs, and therefore those variables have diagnostic potential. At the same time the significantly different variables between groups can be appreciated as risk or protective factors for attracting EHM compared to another acute neurological disease. This type of control group has not been used previously for risk analysis of EHM.
Limitations include the retrospective nature of this work, the relatively limited case numbers and reporting by different veterinarians mostly under field conditions. However, potential bias has been reduced to a minimum by the use of a structured network, standardized clinical forms and case classification by an expert committee.
Conclusion
This study is the first to provide a thorough description of French EHM cases, including outbreaks and a high percentage of isolated cases. Although the clinical picture can be variable, the history and clinical examination of acutely neurologically affected horses can potentially be a valuable help to recognize EHM cases early, and to select those cases that would need further laboratory testing and immediate infection control measures. In addition, risk factors for EHM were identified and although in a different geographic location and study setup they were largely in accordance with other studies, therefore strengthening their significance in the spread of EHM.
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